

U. S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Substitute for Form 1449/PTO			<i>Complete if Known</i>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			Application Number	10/643,589	
(Use as many sheets as necessary)			Filing Date	August 18, 2003	
			First Named Inventor	Debra D. Pittman	
			Art Unit	1649	
			Examiner Name	G. S. Emch	
Sheet	1	of	1	Attorney Docket Number	WYTH-P01-002

U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code <sup>4</sup> -Number <sup>5</sup> -Kind Code <sup>6</sup> (if known)	MM-DD-YYYY		T
BA1	WO 09/06476 A1	03-31-1994	Immunex Corporation		
BB1	WO 01/62905 A2	08-30-2001	Immunex Corporation		
BC1	WO 02/12345 A2	02-14-2002	Zymogenetics, Inc.		
BD1	WO 02/08272 A2	01-31-2002	Schering Aktiengesellschaft		
BE1	WO 02/29072 A2	04-11-2002	Novartis AG		

## NON-PATENT LITERATURE DOCUMENTS

Examiner initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CK	Harris et al., "Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo," <i>Clin. Exp. Immunol.</i> , Vol. 129, pp. 198-207 (2002).	
	CL	Weinblatt et al., "A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate," <i>The New England Journal of Medicine</i> , Vol. 340(4), pp. 253-259 (1999).	

Examiner Signature	/Gregory Emch/	Date Considered	11/20/2009
-----------------------	----------------	--------------------	------------

<sup>4</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>5</sup>Applicant's unique citation designation number (optional) See Kindis Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>6</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST 16). <sup>7</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>8</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. <sup>9</sup>Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./